News about various clinical trials we are participating in.
Theralase has provided an update on the ongoing clinical study of Ruvidar (aka TLD1433) to treat bladder cancer. Key results indicate Total Response (CR + IR) 72.1% (49/68) of patients achieved complete destruction of their bladder cancer at any point in time and 27.9% (19/68) had a duration of this…
The Phase 1b clinical trial is detailed in a new article in European Urology Open Science.
180 days post single treatment results: 45% complete response, 22% partial response, 11% no response, 22% yet undetermined (n=11). Taken from the Theralase 2020Q4 newsletter.
The U.S. Food and Drug Administration has granted Fast Track Designation to the Phase II Non-Muscle Invasive Bladder Cancer clinical study, opening the possibility of an Accelerated Approval and Priority Review. More details can be found at the Theralase press release.